CARDIORENAL SYNDROME: THE REVIEW OF CURRENT UNDERSTANDING
Introduction. The kidneys and heart rely on each other to function properly. For the kidneys to function, they require adequate blood flow, oxygen delivery and nutrients. If heart failure develops, cardiac output is reduced, which results in decreased renal blood flow, which can lead to reversible and sometimes irreversible kidney damage. For the heart to function, regulation of extracellular volume is required. If the extracellular volume is too low, the volume of blood is insufficient to maintain cardiac output, and if the extracellular volume is too large, fluid leaks out of the capillaries, resulting in edema.
Purpose. To study the relationship of the dynamic balance of the “kidney-heart” system in health and disease.
Material and methods. Review of modern and foreign literary sources; methods – description, analysis, abstracting.
Results and its discussion. 5 forms of cardiorenal syndrome, peculiarities of classification, pathogenesis, clinical manifestations, dynamics of imbalance in the “kidney-heart” system, issues of correction of these disorders are analyzed. They include the treatment of kidney diseases and cardiovascular pathology, prevention of the development of cardiovascular failure in accordance with modern recommendations; diet; quitting smoking, alcohol, nephrotoxic substances; control of body weight, blood pressure, glycemia; the use of angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists or angiotensin receptor blockers, statins; decrease in intra-abdominal pressure and others.
Findings. Approaches to the prevention and treatment of cardiorenal syndrome in patients with kidney and heart damage are important. It is necessary to develop and introduce new approaches to nephroprotection in patients with cardiorenal syndrome, which is possible with the joint work of a multidisciplinary team.
2. Ronco C, Bellasi A, Di Lullo L. Cardiorenal Syndrome: An Overview. Adv Chronic Kidney Dis. 2018; 25(5):382-390. doi:10.1053/j.ackd.2018.08.004.
3. National Heart, Lung, and Blood Institute. NHLBI Working Group: cardio-renal connections in heart failure and cardiovascular disease, 2004. 2004. https://www.nhlbi.nih.gov/events/2004/cardio-renal-connections-heart-failure-and-cardiovascular-disease. Accessed March 05, 2020.
4. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo
G, Zamperetti N, Ponikowski P. Cardio-renal syndromes: report from the Consensus Conference of the Acute Dialysis Quality Initiative.Eur Heart J. 2010; 31:703–711.
5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome.J Am Coll Cardiol. 2008; 52:1527–1539. doi: 10.1016/j.jacc.2008.07.051
6. Liang K.V, Williams A.W. Greene E.L. Redfield M.M. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;
7. Haldeman G.A, Croft J.B. Giles W.H, Rashidee A. Hospitalization of patients with heart failure: national hospital discharge survey 1985 to 1995. Am Heart J. 1999; 137:352–360.
8. Mebazaa A, Gheorghiade M, Pina I.L, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008; 36:S129–S139.
9. Bargshaw S.M. Cruz D.M. Aspromonte N. Epidemiology of cardio –renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25:1406– 1416.
10. Damman K. Navis G. Voors A.A. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599–608.
11. Hanada S., Takewa Y., Mizuno T., Tsukiyan T., Taenaka Y., Tatsumi E. Effect of the technique for assisting renal blood circulation on ischemic
kidney in acute cardiorenal syndrome. J Artif Organs. 2012;15:140–145.
12. Stevenson L.W., Perloff J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888.
13. Mullens W., Abrahams Z., Francis G.S. Importance of venous congestion for worsening of renal function in advanced decompensated heart
failure. J Am Coll Cardiol. 2009;53:589–596.
14. Uthoff H., Breidthardt T., Klima T. Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail. 2011;13:432–439.
15. Braam B., Cupples W.A., Joles J.A., Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure.
Heart Fail Rev. 2012;17:161–175.
16. De Silva R., Loh H., Rigby A.S. Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography. Am J Cardiol. 2007;100:273–279.
17. Nohria A., Tsang S.W., Fang J.C. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804.
18. Havasi A, Borkan S.C. Apoptosis and acute kidney injury. Kidney Int. 2011;80:29–40.
19. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol. 2003;14(Suppl. 1):S55–61.
20. Akcay A., Nguyen Q., Edelstein C.L. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009:137072.
21. Cruz D.N., Schmidt-Ott K.M., Vescovo G. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol. 2013;182:117–136.
22. Setoguchi S., Stevenson L.W., Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am
Heart J. 2007;154(2):260–266.
23. Kanjanahattakij N, Sirinvaravong N, Aguilar F, Agrawal A, Krishnamoorthy P, Gupta S. High right ventricular stroke work index is associated with worse kidney function in patients with heart failure with preserved ejection fraction.Cardiorenal Med. 2018; 8:123–129. doi: 10.1159/000486629
24. Remuzzi G., Cattaneo D., Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19(8):1459–1462.
25. Colombo P.C., Ganda A., Lin J. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012;17(2):177–190.
26. Yap S.C., Lee H.T. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology. 2012;116(May (5)):1139–1148.
27. Prabhu S.D. Cytokine-induced modulation of cardiac function. Circ Res. 2004;95(December (12)):1140–1153.
28. Kingma J.G., Jr., Vincent C., Rouleau J.R., Kingma I. Influence of acute renal failure on coronary vasoregulation in dogs. J Am Soc Nephrol. 2006;17(May (5)):1316–1324.
29. Lezaic V., Tirmenstajn-Jankovic B., Bukvic D. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol. 2009;71(1):21–29.
30. Di Lullo L., Floccari F., Santoboni A. Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol. 2013;26(July (4)):739–744.
31. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int. 2005;68(Suppl. 99):S25–S29.
32. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97.
33. Chan C.T., Levin N.W., Chertow G.M. Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol. 2010;5(10):1821–1827.
34. Winkelmayer W.C., Patrick A.R., Liu J. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22(2):349–357.
35. Cai Q., Mukku V.K., Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9(November (4)):331–339.
36. Kingma J.G., Jr., Vincent C., Rouleau J.R., Kingma I. Influence of acute renal failure on coronary vasoregulation in dogs. J Am Soc Nephrol.
37. Lok D.J., Lok S.I., Bruggink-André de la Porte P.W. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102(February (2)):103–110.
38. Krag A., Bendtsen F., Burroughs A.K., Møller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79(July (1)):53–55.
39. Lundy D.J., Trzeciak S. Microcirculatory dysfunction in sepsis. Crit Care Clin. 2009;25(4):721–731.
40. Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirilä-Waris K, Sund R, Harjola VP; FINN-AKVA Study Group: Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31:2791-2798.
41. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P: Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med. 2012;50:1533-1545.
42. Di Lullo L, Floccari F, Granata A, D’Amelio A, Rivera R, Fiorini F, Malaguti M, Timio M: Ultrasonography: Ariadne’s thread in the diagnosis of cardiorenal syndrome. Cardiorenal Med. 2012;2:11-17.
43. Hollenberg SM, Kevinsky CJ, Parrillo JE: Cardiogenic shock. Ann Intern Med. 1999;131:47-59.
44. Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT: Development and validation of a general population renal risk score. Clin J Am Soc Nephrol. 2011;6:1731-1738.
45. Cruz DN, Fard A, Clementi A, Ronco C, Maisel A: Role of biomarkers in the diagnosis and management of cardio-renal syndromes. Semin Nephrol. 2012;32:79-92.
46. Shah SU, Anjum S, Littler WA: Use of diuretics in cardiovascular diseases: (1) heart failure. Postgrad Med J. 2004;80:201-205.
47. Butler J, Forman DE, Abraham WT, et al: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338.
48. Costanzo MR: Ultrafiltration in the management of heart failure. Curr Opin Crit Care. 2008;14:524- 530.
49. Di Lullo L, Barbera V, Santoboni A, Bellasi A, Cozzolino M, De Pascalis A, Rivera R, Balducci A, Russo D, Ronco C: Troponins and chronic kidney
disease. G Ital Nefrol. 2015;32.
50. Chuasuwan A, Kellum JA: Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol. 2012;32:31-39.
51. Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in
dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-1444.
52. Reinhart K, et al: New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbio Rev. 2012;25:609-634.
53. Ronco C, Di Lullo L: Cardiorenal syndrome. Heart Fail Clin. 2014;10:251-280.
54. Nakamura M, et al: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine
This work is licensed under a Creative Commons Attribution 4.0 International License.